Compare CLNN & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLNN | SRTS |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.4M | 48.9M |
| IPO Year | 2021 | 2016 |
| Metric | CLNN | SRTS |
|---|---|---|
| Price | $4.36 | $3.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $33.75 | $7.00 |
| AVG Volume (30 Days) | ★ 119.0K | 38.1K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $200,000.00 | ★ $27,482,000.00 |
| Revenue This Year | $17.64 | $2.00 |
| Revenue Next Year | $19,516.77 | $34.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.25 | $2.66 |
| 52 Week High | $13.50 | $5.49 |
| Indicator | CLNN | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 44.31 |
| Support Level | $3.92 | $2.80 |
| Resistance Level | $4.70 | $3.25 |
| Average True Range (ATR) | 0.38 | 0.16 |
| MACD | 0.09 | -0.03 |
| Stochastic Oscillator | 96.64 | 8.45 |
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.